Glioma is the most common primary malignant tumor in the brain.Although through standardized treatment,including the largest range of surgical resection and subsequent radiotherapy and chemotherapy,the morbidity and mortality is still high,so we need a new treatment.The oncolytic virus antitumor concept was mentioned in the early 20th century,which is a kind of antitumor virus,people found that cancer patients infected with certain viruses,the tumor was gradually disappeared.With the development of Molecular Biology,Immunology,Virology and Genetic Engineering,oncolytic virus becomes a new method of tumors treatment,which attracts more and more researchers' attention,so we made an overview in the antitumor principle of oncolytic virus and its clinical application in the treatment of glioma.

Purpose: Isocitrate dehydrogenase 1 (IDH1) mutations are the most common genetic abnormalities in low-grade gliomas and secondary glioblastomas. Glioma patients with these mutations had better clinical outcomes. However, the effect of IDH1 mutation on drug sensitivity is still under debate. Materials and Methods: IDH1-R132H mutant cells were established by lentivirus. IDH1-R132H protein expression was confirmed by western blot. The expression of ataxia telangiectasia mutated (ATM) signaling pathway and apoptosis-related proteins were detected by immunofluorescence and western blot. Temozolomide (TMZ) induced cell apoptosis was detected by flow cytometry. Tumor cell proliferation was detected by Cell Counting Kit-8. In vivo nude mice were used to confirm the in vitro roles of IDH1 mutation. Results: We established glioma cell lines that expressed IDH1-R132H mutation stably. We found that TMZ inhibited glioma cells proliferation more significantly in IDH1 mutant cells compared to wild type. The IC50 of TMZ in IDH1-R132H mutant group was less than half that of wild-type group (p < 0.01). TMZ significantly induced more DNA damage (quantification of γH2AX expression in IDH1 mutation vs. wild type, p < 0.05) and apoptosis (quantification of AnnexinV+propidium iodide–cells in IDH1 mutation versus wild type, p < 0.01) in IDH1 mutant gliomas compared to wild-type gliomas. The ATM-associated DNA repair signal was impaired in IDH1 mutant cells. Inhibiting the ATM/checkpoint kinase 2DNA repair pathway further sensitized IDH1 mutant glioma cells to chemotherapy. We found that IDH1 mutation significantly inhibited tumor growth in vivo (the tumor size was analyzed statistically, p < 0.05). Moreover, we confirmed that gliomas with IDH1 mutation were more sensitive to TMZ in vivo compared to wild type significantly and the results were consistent with the in vitro experiment. Conclusion These results provide evidence that combination of TMZ and ATM inhibitor enhances the antitumor effect in IDH1 mutant gliomas.

Purpose: Isocitrate dehydrogenase 1 (IDH1) mutations are the most common genetic abnormalities in low-grade gliomas and secondary glioblastomas. Glioma patients with these mutations had better clinical outcomes. However, the effect of IDH1 mutation on drug sensitivity is still under debate. Materials and Methods: IDH1-R132H mutant cells were established by lentivirus. IDH1-R132H protein expression was confirmed by western blot. The expression of ataxia telangiectasia mutated (ATM) signaling pathway and apoptosis-related proteins were detected by immunofluorescence and western blot. Temozolomide (TMZ) induced cell apoptosis was detected by flow cytometry. Tumor cell proliferation was detected by Cell Counting Kit-8. In vivo nude mice were used to confirm the in vitro roles of IDH1 mutation. Results: We established glioma cell lines that expressed IDH1-R132H mutation stably. We found that TMZ inhibited glioma cells proliferation more significantly in IDH1 mutant cells compared to wild type. The IC50 of TMZ in IDH1-R132H mutant group was less than half that of wild-type group (p < 0.01). TMZ significantly induced more DNA damage (quantification of γH2AX expression in IDH1 mutation vs. wild type, p < 0.05) and apoptosis (quantification of AnnexinV+propidium iodide–cells in IDH1 mutation versus wild type, p < 0.01) in IDH1 mutant gliomas compared to wild-type gliomas. The ATM-associated DNA repair signal was impaired in IDH1 mutant cells. Inhibiting the ATM/checkpoint kinase 2DNA repair pathway further sensitized IDH1 mutant glioma cells to chemotherapy. We found that IDH1 mutation significantly inhibited tumor growth in vivo (the tumor size was analyzed statistically, p < 0.05). Moreover, we confirmed that gliomas with IDH1 mutation were more sensitive to TMZ in vivo compared to wild type significantly and the results were consistent with the in vitro experiment. Conclusion These results provide evidence that combination of TMZ and ATM inhibitor enhances the antitumor effect in IDH1 mutant gliomas.

The standardized training system for physicians has been implemented for many years in China. Based on the current situation of neurosurgery specialist training and the sub-professional development, the study discusses the specific plan and direction of glioma sub-professional physicians training from the aspects of glioma sub-professional physicians training outline, training content, requirements of glioma sub-professional training base, training assessment methods and training management. It provided reference for the training of neurosurgical glioma professionals in China, so as to make glioma receive comprehensive and standardized treatment.

Objective:To compare the pregnancy outcome before the implementation of management specification of cervical ripening with dinoprostone suppository with that after the implementation and explore its safety for cervical ripening .Methods:The clinical data of 612 puerperants ,who received cervical ripening with dinoprostone suppository and delivered in First Mater‐nal and Infant Hospital Affiliated to Tongji University during Sep 2012 and Feb 2014 ,were retrospectively analyzed .The man‐agement specification of cervical ripening with dinoprostone had been implemented since Apr 2013 .The maternal and neonatal outcomes ,as well as the rate of adverse reactions ,before and after the implementation of management specification of cervical ripening with dinoprostone suppository were compared with each other ,so as to explore its effects on pregnancy outcome .Re‐sults:There were 449 puerperants receiving cervical ripening with suppository before the implementation of management speci‐fication in Apr 2013 and 163 cases after that .Totally 413 cases(67 .5% ) were induced labour successfully .The success rates of inducting labor within 48 h ,24 h and 12 h after the implementation of management specification were lower than that before the implementation of management specification ,but there was no significant difference .The cesarean rate was 27 .1% and there was no statistically significant difference between the cesarean rate before the implementation of management specification and that after the implementation .There was no statistically significant difference in Apgar score and admission rate to ICU between the two groups .The incidence rates of tachysystole and hypertonus ,meconium‐stained amniotic fluid after the implementation of specification were significantly lower than that before the implementation ,and the difference was statistically significant(P<0 .05) .There was no statistically significant difference regarding the incidence rates of uterine hyperstimulation and the clinical chorioamnionitis .There was no occurrence of complications as amniotic fluid embolism and severe perineal laceration .Conclusions:Di‐noprostone suppository is a safe and effective method for cervical ripening and labor induction .The implementation of management speci‐fication is conducive to protecting maternal and infant and reducing the adverse pregnancy outcomes .

Chronic refractory wound (CRW) is one of the most challengeable issues in clinic due to complex pathogenesis, long course of disease and poor prognosis. Experts need to conduct systematic summary for the diagnosis and treatment of CRW due to complex pathogenesis and poor prognosis, and standard guidelines for the diagnosis and treatment of CRW should be created. The Guideline forthe diagnosis and treatment of chronic refractory wounds in orthopedic trauma patients ( version 2023) was created by the expert group organized by the Chinese Association of Orthopedic Surgeons, Chinese Orthopedic Association, Chinese Society of Traumatology, and Trauma Orthopedics and Multiple Traumatology Group of Emergency Resuscitation Committee of Chinese Medical Doctor Association after the clinical problems were chosen based on demand-driven principles and principles of evidence-based medicine. The guideline systematically elaborated CRW from aspects of the epidemiology, diagnosis, treatment, postoperative management, complication prevention and comorbidity management, and rehabilitation and health education, and 9 recommendations were finally proposed to provide a reliable clinical reference for the diagnosis and treatment of CRW.